Warning: The NCBI web site requires JavaScript to function. more...
Triple-negative breast cancers are increased in black women regardless of age or body mass index.
Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M, Blanchard RA, Lee JC, King TC, Rosenberg CL.
Breast Cancer Res. 2009;11(2):R18. Epub 2009 Mar 25.
Related citations
Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V.
Cancer. 2007 May 1;109(9):1721-8.
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.
Elledge RM, Clark GM, Chamness GC, Osborne CK.
J Natl Cancer Inst. 1994 May 4;86(9):705-12.
The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V.
Cancer. 2008 Feb 15;112(4):737-47.
High prevalence of triple-negative tumors in an urban cancer center.
Lund MJ, Butler EN, Bumpers HL, Okoli J, Rizzo M, Hatchett N, Green VL, Brawley OW, Oprea-Ilies GM, Gabram SG.
Cancer. 2008 Aug 1;113(3):608-15.
Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
Cancer. 2008 Mar 1;112(5):995-1000.
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW.
Breast Cancer Res Treat. 2009 Jan;113(2):357-70. Epub 2008 Mar 7.
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC.
JAMA. 2006 Jun 7;295(21):2492-502.
Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer.
Dignam JJ, Wieand K, Johnson KA, Raich P, Anderson SJ, Somkin C, Wickerham DL.
Breast Cancer Res Treat. 2006 Jun;97(3):245-54. Epub 2005 Dec 6.
Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.
J Surg Res. 2007 Nov;143(1):109-18.
Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA, Bauer KR, Brown MM, Caggiano V.
Breast J. 2009 Nov-Dec;15(6):593-602. Epub 2009 Sep 17.
Associations of weight, weight change, and body mass with breast cancer risk in Hispanic and non-Hispanic white women.
Wenten M, Gilliland FD, Baumgartner K, Samet JM.
Ann Epidemiol. 2002 Aug;12(6):435-4.
Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases.
Gapstur SM, Dupuis J, Gann P, Collila S, Winchester DP.
Cancer. 1996 Apr 15;77(8):1465-71.
The epidemiology of triple-negative breast cancer, including race.
Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW.
Cancer Causes Control. 2009 Sep;20(7):1071-82. Epub 2009 Apr 3.
Can obesity explain the racial difference in stage of breast cancer at diagnosis between black and white women?
Cui Y, Whiteman MK, Langenberg P, Sexton M, Tkaczuk KH, Flaws JA, Bush TL.
J Womens Health Gend Based Med. 2002 Jul-Aug;11(6):527-36.
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.
Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT, Hennessy BT, Hortobagyi GN, Gonzalez-Angulo AM.
J Clin Oncol. 2009 Jan 10;27(2):220-6. Epub 2008 Dec 1.
The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review.
Vona-Davis L, Rose DP.
J Womens Health (Larchmt). 2009 Jun;18(6):883-93. Review.
Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer.
Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I, Christiaens MR.
Ann Oncol. 2005 Nov;16(11):1755-61. Epub 2005 Aug 5.
Obesity and risk of the less commonly diagnosed subtypes of breast cancer.
Stark A, Schultz D, Kapke A, Nadkarni P, Burke M, Linden M, Raju U.
Eur J Surg Oncol. 2009 Sep;35(9):928-35. Epub 2009 Jan 1.
p53 as a marker of prognosis in African-American women with breast cancer.
Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S.
Ann Surg Oncol. 2010 May;17(5):1398-405. Epub 2010 Jan 5.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on